Back to top
more

Collegium Pharmaceutical, Inc. (COLL)

(Real Time Quote from BATS)

$16.63 USD

16.63
146,036

+0.85 (5.39%)

Updated Aug 3, 2020 01:11 PM ET

4-Sell of 5       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.33%
17.77%
9.37%
4.88%
1.79%
10.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value D Growth B Momentum C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for COLL

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Collegium Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 170 147 119 153 96
Receivables 73 78 10 2 0
Notes Receivable 0 0 0 0 0
Inventories 10 8 2 1 0
Other Current Assets 3 5 3 2 1
Total Current Assets 256 238 133 159 97
Net Property & Equipment 12 9 2 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 30 44 0 2 0
Deposits & Other Assets 9 0 0 0 0
Total Assets 306 291 136 162 98
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 0 0
Accounts Payable 6 12 6 9 4
Current Portion Long-Term Debt 4 2 1 3 3
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 191 175 24 9 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 5 0
Total Current Liabilities 202 189 31 26 8
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 17 10 0 1 4
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 1 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 219 200 31 27 13
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 447 429 402 358 214
Retained Earnings -360 -337 -298 -223 -129
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 87 92 104 135 85
Total Liabilities & Shareholder's Equity 306 291 136 162 98
Total Common Equity 87 92 104 135 85
Shares Outstanding 33.50 33.20 32.50 28.60 23.40
Book Value Per Share 2.61 2.76 3.20 4.72 3.64

Fiscal Year End for Collegium Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Assets          
Cash & Equivalents NA 116 170 154 149
Receivables NA 85 73 84 81
Notes Receivable NA 0 0 0 0
Inventories NA 16 10 9 10
Other Current Assets NA 6 3 3 5
Total Current Assets NA 224 256 250 245
Net Property & Equipment NA 13 12 12 10
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 386 30 33 37
Deposits & Other Assets NA 12 9 9 10
Total Assets NA 635 306 304 302
Liabilities & Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 6 6 12 11
Current Portion Long-Term Debt NA 48 4 4 3
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 191 191 186 183
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 244 202 201 196
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 94 0 0 0
Long-Term Debt NA 155 17 18 19
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 494 219 220 216
Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 500 447 442 437
Retained Earnings NA -359 -360 -358 -352
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 141 87 84 86
Total Liabilities & Shareholder's Equity NA 635 306 304 302
Total Common Equity 0 141 87 84 86
Shares Outstanding 34.30 34.30 33.50 33.50 33.30
Book Value Per Share 0.00 4.11 2.61 2.52 2.58